Alto Neuroscience, Inc. (ANRO)

Alto Neuroscience, Inc. is trading at $33.80, up 0.58% on the session. The 50 day average sits at $25.79 and the 200 day at $n/a, which puts the stock in a mixed technical position. RSI is at 70.3, which reads as overbought, and MACD is bullish crossover. Volume is volume spike.

The nearest support is around $25.80 with resistance near $33.67, so that band frames the current range. Average daily movement is roughly $2.03, or about 6.0% of the share price, which is what any stop placement has to allow for. The overall health score of 65 out of 100 combines a trend score of 75, momentum of 84 and a risk score of 22.

Alto Neuroscience, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company's product pipeline includes ALTO-100, which is in Phase 2b clinical trial for the treatment of patients with bipolar depression (BPD). It also develops ALTO-300, a small molecule melatonergic agonist and serotonergic antagonist with antidepressant properties, which is in Phase 2b clinical trial to treat patients with major depressive disorder (MDD); ALTO-101, a novel small molecule phosphodiesterase 4 inhibitor that is in Phase 2 proof-of-concept (POC) trial for the treatment of cognitive impairment associated with schizophrenia; ALTO-203, a novel small-molecule histamine H3 receptor inverse agonist, which is in Phase 2 POC trial to treat patients with MDD and higher levels of anhedonia; ALTO-202, an investigational orally bioavailable antagonist of the GluN2B subunit of the NMDA receptor that is in Phase 1 clinical trial for the treatment of MDD; and ALTO-208, a fixed-dose combination of pramipexole and aprepitant, an antiemetic, neurokinin-1 (NK-1) receptor antagonist for patients with Parkinson's disease for patients with Parkinson's disease. The company was incorporated in 2019 and is headquartered in Mountain View, California.